BRIEF — Rezolute Announces Completion Of Enrollment In Phase 3 Uplift Study Of Ersodetug In Tumor Hyperinsulinism
Oct 14 (Reuters) — Rezolute, Inc.: Rezolute Announces Completion Of Enrollment In Phase 3 Uplift Study Of Ersodetug In Tumor Hyperinsulinism Rezolute - Completes Enrollment In Phase 3 Uplift Study; Topline Results Expected Mid-december 2026 Rezolute - Primary Endpoint Is 50% Reduction In Glucose Infusion Rate Within 8